Mitesh Patel
The use of β2-agonist therapy before hospital attendance for severe asthma exacerbations: a post-hoc analysis
Patel, Mitesh; Pilcher, Janine; Hancox, Robert J.; Sheahan, Davitt; Pritchard, Alison; Braithwaite, Irene; Shaw, Dominick; Black, Peter; Weatherall, Mark; Beasley, Richard
Authors
Janine Pilcher
Robert J. Hancox
Davitt Sheahan
Alison Pritchard
Irene Braithwaite
Dominick Shaw
Peter Black
Mark Weatherall
Richard Beasley
Abstract
Background:
Patterns of inhaled β2-agonist therapy use during severe asthma exacerbations before hospital attendance are poorly understood.
Aims:
To assess β2-agonist use prior to hospital attendance.
Methods:
We undertook an exploratory post hoc analysis of data from a 6-month clinical trial of 303 patients randomised to combination budesonide/formoterol inhaler according to a Single combination inhaler as Maintenance And Reliever Therapy regimen (‘SMART’) or fixed-dose budesonide/formoterol with salbutamol as reliever (‘Standard’). Patterns of β2-agonist use for 14 days before hospital attendance with a severe asthma exacerbation were determined by electronic monitoring of inhaler use.
Results:
There were 22 hospital attendances in 16 patients during the study. Seven and nine hospital attendances were eligible for analysis in the SMART and Standard groups, respectively. In both regimens, β2-agonist use increased before hospital attendance, with a median (range) maximum daily number of actuations of 14 (9 to 63) budesonide/formoterol in SMART and 46 (6 to 95) salbutamol in Standard with 4 (0 to 10) budesonide/formoterol actuations on the day of maximal salbutamol use. There was delay in obtaining medical review despite high β2-agonist use, in 9/16 patients.
Different patterns of use were observed, including repeated days of no inhaled corticosteroid despite marked salbutamol use, which occurred in 3/9 patients in the Standard group.
Conclusions:
Delay in obtaining medical review in association with high β2-agonist use is common in patients before hospital presentation with severe exacerbations of asthma. The SMART regimen reduced nonadherence with inhaled corticosteroid therapy during severe exacerbations.
Citation
Patel, M., Pilcher, J., Hancox, R. J., Sheahan, D., Pritchard, A., Braithwaite, I., …Beasley, R. (2015). The use of β2-agonist therapy before hospital attendance for severe asthma exacerbations: a post-hoc analysis. npj Primary Care Respiratory Medicine, 25, 1-9. https://doi.org/10.1038/npjpcrm.2014.99
Journal Article Type | Article |
---|---|
Acceptance Date | Aug 4, 2014 |
Online Publication Date | Jan 8, 2015 |
Publication Date | Jan 8, 2015 |
Deposit Date | Oct 24, 2016 |
Publicly Available Date | Oct 24, 2016 |
Journal | npj Primary Care Respiratory Medicine |
Electronic ISSN | 2055-1010 |
Publisher | Nature Publishing Group |
Peer Reviewed | Peer Reviewed |
Volume | 25 |
Article Number | 14099 |
Pages | 1-9 |
DOI | https://doi.org/10.1038/npjpcrm.2014.99 |
Public URL | https://nottingham-repository.worktribe.com/output/985285 |
Publisher URL | http://www.nature.com/articles/npjpcrm201499 |
Contract Date | Oct 24, 2016 |
Files
npjpcrm201499.pdf
(493 Kb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by-nc-nd/4.0/
Copyright Statement
Copyright information regarding this work can be found at the following address: http://creativecommons.org/licenses/by-nc-nd/4.0
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search